World Data Showing UZEDY (risperidone) Outperforms Other Long

Mayer Brown advised underwriters on Teva Pharmaceutical's $4.9 billion senior notes offering, which closed today. The firm's team included partners David Becker, Rob Mathews, and Ben Bierwirth, who recently joined Mayer Brown and have previously worked with Teva.

Teva presented new data on Olanzapine LAI and UZEDY® at Psych Congress 2026. Olanzapine LAI, in Phase 3 trials, showed 56% stabilization and 4% relapse rate among stabilized participants. UZEDY® data indicated better treatment continuity and lower healthcare costs. Olanzapine LAI awaits FDA decision in Q4 2026. Both treatments use Medincell's BEPO® technology.

Teva presented new data from its phase 3 SOLARIS study on olanzapine LAI, showing 56% of participants achieved clinical stabilization. The FDA decision on the treatment is expected in Q4 2026. Teva submitted its marketing application in December 2025, accepted by the FDA in February 2026.

Teva Pharmaceuticals presented post hoc data from the SOLARIS Phase 3 trial for TEV-'749, a once-monthly subcutaneous injectable olanzapine treatment for schizophrenia. Over half of participants achieved stabilization, and 21% met remission criteria. The data were presented at Psych Congress 2026. Teva anticipates an FDA decision on TEV-'749 in Q4 2026.

Teva presented post hoc data showing 80% of schizophrenia patients stabilized with TEV-749 in the SOLARIS Phase 3 trial. The once-monthly subcutaneous olanzapine formulation aims to reduce post-injection monitoring burden. Teva targets patients switching from oral antipsychotics. Regulatory approval and label language will impact adoption.

Teva Pharmaceuticals presented Phase 3 trial data for TEV-’749, an investigational once-monthly olanzapine injection for schizophrenia. The study showed 56% of participants achieved stabilization, and 21% met remission criteria. The drug uses Medincell's SteadyTeq technology and is not yet approved. FDA decision expected in Q4 2026.